Bellerophon plunges after lead drug flops in study; Leon-nanodrugs raises €18.5M;

@FierceBiotech: Cutting-edge research centers back Deerfield's $550M biotech venture fund. Story | Follow @FierceBiotech

@JohnCFierce: This just in, $SNY has decided to outsource all pipeline work and restrict R&D effort to writing checks. $REGN $ALNY | Follow @JohnCFierce

@DamianFierce: Marc Beer resignation PR includes a line about continuing "the company's commitment to high integrity and ethics." | Follow @DamianFierce

> Shares of Bellerophon Therapeutics plunged 60% after the biotech reported that its injectable heart drug--bioabsorbable cardiac matrix, or BCM--failed in a study. Story

> Germany's leon-nanodrugs raised €18.5 million in Series A financing. Release

> The FDA has green-lighted FibroGen's NDA for FG-3019 in patients with Duchenne muscular dystrophy. Release

> France's Guerbet is buying Mallinckrodt's contrast media and delivery systems business. Release

Medical Device News

@FierceMedDev: Docs dole out recs for reducing fetal ultrasound procedures in the U.S. Story | Follow @FierceMedDev

@EmilyWFierce: #FDA launches probe into safety of common MRI contrast agent. Article | Follow @EmilyWFierce

> Cepheid readies for 2016 launch of point-of-care molecular Dx system for use anywhere. More

> Micro-cap Nephros secures up to $10M to back its alternative to hemodialysis. Story

Pharma News

@FiercePharma: $BMY CEO talks up immuno-oncology space, coming hep C competition in Japan. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Lupin lands its first US manufacturing site with $880M deal for GAVIS, 6-year-old NJ firm. More | Follow @EricPFierce

@CarlyHFierce: About that brand/generics hybrid thing? Make that brands only, Allergan says with Teva deal. News | Follow @CarlyHFierce

> Pfizer lifts guidance as Prevnar, Ibrance trigger Q2 beats. More

> Hikma shells out $2.65B for Boehringer's U.S. generics business. Story

Drug Delivery News

> IPOs: EyeGate tries again following deal with Valeant, Parkinson's specialist to debut soon. More

> Alnylam launches trial of one of its RNAi candidates. Article

> Pill holds a ring-shaped device that could deliver drugs to the stomach long-term. Story

> ASU team offers precise DNA origami technique with novel shapes and delivery potential. More

> Ra Pharma gets $58.5M to challenge a rare disease's intravenous incumbent. Article

Pharma Manufacturing News

> Avista Pharma snaps up NC manufacturing facility from rival Scynexis. Report

> Teva expands recall of cancer drug Adrucil. Story

> Androxy returns to market after 9-month lapse. News

> EU ban on more than 700 drugs set for Aug. 21. Item

> Hospira recall of ketorolac now close to 40 million vials. Article

Pharma Asia News

> Fallout from India's GVK means $1B lost in drug exports by March 2016. News

> Trans-Pacific Partnership impasse on data exclusivity for biologics softens. Story

> Roche COO O'Day highlights emerging markets trends on Q2 call. More

> Eli Lilly execs on Q2 call discuss Japan opportunities, China slowdown. Article

> EU-wide ban starts Aug. 21 on 700-plus drugs tested by India's GVK Bio Sciences. Report

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.